Open-source automated insulin delivery (AID) systems in patients with type 1 diabetes was studied in the CREATE trial and is discussed by Dr Martin de Bock (University of Otago, Christchurch, New Zealand). Open-source AID systems were developed by people with diabetes and shared openly. They combine an insulin pump, continuous glucose monitor and an algorithm that adjusts insulin delivery automatically every five minutes with the purpose of keeping glucose levels in target range.
The abstract entitled ‘The CREATE Trial: Randomized Clinical Trial Comparing Open-Source Automated Insulin Delivery with Sensor Augmented Pump Therapy in Type 1 Diabetes‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- Could you give us a brief overview of open-source automated insulin delivery systems (AID) and sensor-augmented pump therapy? (0:15)
- What were the aims, design and patient population of the CREATE trial? (0:50)
- How did the two treatment arms compare in terms of time in range? (1:23)
- What were study findings in terms of hypoglycaemia, diabetic ketoacidosis events, and treatment discontinuation? (1:51)
- Which patients were most likely to benefit from AID? (2:16)
Disclosures: Martin de Bock has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Diabetes
Clipper Young & Shirley Wong, ADCES 2022: New horizons in type 2 diabetes management and cardiorenal risk reduction: A pharmacotherapeutic update
Cardiorenal complications in people with type 2 diabetes illustrates a link between the heart and the kidneys, which can be exacerbated by other comorbidities, such as hypertension, dyslipidaemia, and obesity. In this touchENDOCRINOLOGY interview, Dr Clipper Young and Shirley Wong (Touro University California College of Osteopathic Medicine, Vallejo, CA, USA) firstly discuss diabetes management and […]
Jennifer Clements, ADCES 2022: Efficacy and safety of once-daily vs twice-daily insulin glargine in non-critically ill patients with diabetes
In this touchENDOCRINOLOGY interview, Prof. Jennifer Clements (University of South Carolina, College of Pharmacy, Columbia, SC, USA) joins us to discuss a study investigating the efficacy and safety of once-daily vs twice-daily insulin glargine in non-critically ill patients. The abstract entitled: ‘A Retrospective Analysis of Once-daily versus Twice-daily Dosing of Insulin Glargine in Non-critically Ill […]
Jennifer Clements, ADCES 2022: Clinical implications of SGLT-2 inhibitors for chronic kidney disease in people with type 2 diabetes
Chronic kidney disease in people with type 2 diabetes is heavily prevalent, and the main causes are diabetes and hypertension. In this touchENDOCRINOLOGY interview, Prof. Jennifer Clements (University of South Carolina, College of Pharmacy, Columbia, SC, USA) joins us to discuss the health burden of chronic kidney disease (CKD) in people with type 2 diabetes, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!